- Home
- CNM vs BMRN Comparison
CNM vs BMRN Comparison
Compare CNM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNM | BMRN |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.4B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CNM | BMRN |
|---|---|---|
| Price | $45.34 | $50.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 18 |
| Target Price | $61.55 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 06-09-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.45 | N/A |
| EPS | ★ 2.31 | 0.54 |
| Revenue | ★ $7,647,000,000.00 | $1,313,646,000.00 |
| Revenue This Year | $4.89 | $15.02 |
| Revenue Next Year | $4.21 | $12.23 |
| P/E Ratio | ★ $20.14 | $91.80 |
| Revenue Growth | 2.77 | ★ 17.62 |
| 52 Week Low | $43.96 | $49.26 |
| 52 Week High | $67.18 | $66.28 |
Technical Indicators
Market Signals| Indicator | CNM | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 34.14 |
| Support Level | $43.96 | N/A |
| Resistance Level | $51.56 | $56.91 |
| Average True Range (ATR) | 1.47 | 1.82 |
| MACD | -0.34 | -0.32 |
| Stochastic Oscillator | 9.11 | 9.91 |
Price Performance
Historical ComparisonAbout CNM Core & Main Inc.
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.